• MapLight Therapeutics reported positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in adults with an acute schizophrenia exacerbation.
• The study met its main goal, showing a clinically meaningful improvement in overall schizophrenia symptoms versus placebo at the twice-daily dose.
• A prespecified analysis also showed improved cognitive performance in patients with baseline cognitive impairment, suggesting a benefit beyond symptom control.
• The drug was generally well tolerated, with no serious or drug-related severe adverse events reported.
• MapLight plans an End-of-Phase 2 FDA meeting, moving toward an additional registrational trial intended to support an NDA submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270700PRIMZONEFULLFEED9788316) on July 27, 2026, and is solely responsible for the information contained therein.